Sign up UNITED KINGDOM
Proactive Investors - Run By Investors For Investors

New Epistem chief to start six weeks early

David Budd will now take over on 1 March instead of the middle of April as previously anticipated.
New Epistem chief to start six weeks early
Epistem revealed yesterday its genedrive diagnostic test had been cleared for European clinical trials in Hepatitis C

Epistem Holdings' (LON:EHP) new chief executive is to join six weeks earlier than planned.

David Budd will now take over on 1 March instead of the middle of April as previously anticipated.

Budd has more than 20 years of international commercial and operational experience in diagnostics and medical devices, especially in the molecular field.

He joins from Danaher subsidiary Leica Biosystems where he was last post was general manager of Leica Biosystems Amsterdam.

At Leica Biosystems Newcastle, he had global responsibility for marketing, market research and product launches for diagnostic tests.

Epistem revealed yesterday its genedrive diagnostic test had been cleared for European clinical trials in Hepatitis C (HCV) by the Institut Pasteur in Paris.

Genedrive was launched to test for TB in India last year.

Budd said: “I believe Genedrive is an outstanding molecular diagnostic system with significant near term commercial opportunities in tuberculosis testing and across a wide range of other applications in the future.”

PhilW.jpg
Why Invest In Epistem Holdings Plc? Read More Here

Register here to be notified of future EHP Company articles
View full EHP profile

Epistem Holdings Plc Timeline

Newswire
January 13 2016

Related Articles

rsz_shutterstock_118277080.jpg
January 19 2016
Horizon Discovery is a machine, which keeps motoring, underlined by the life sciences group's positive update on 2015 trading.
Lab-(1).jpg
December 02 2015
Firm aims to expand regenerative medicine and in-vitro diagnostics business
CancerHeadline.jpg
February 24 2016
"We are swiftly moving towards our goal of becoming a clinical-stage development company," said CEO, Dr Tim Mitchell

© Proactive Investors 2016

Proactive Investor UK Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.